Circulating biomarkers of collagen metabolism in arterial hypertension: relevance of target organ damage

被引:29
作者
Morillas, Pedro [1 ]
Quiles, Juan [1 ]
de Andrade, Helder [1 ]
Castillo, Jesus [1 ]
Tarazon, Estefania [2 ]
Rosello, Esther [2 ]
Portoles, Manuel [2 ]
Rivera, Miguel [2 ]
Bertomeu-Martinez, Vicente [1 ]
机构
[1] Hosp Univ San Juan, Dept Cardiol, Arterial Hypertens Unit, Valencia, Spain
[2] Hosp Univ La Fe, Res Ctr, Cardiocirculatory Unit, Valencia, Spain
关键词
arterial remodelling; blood pressure; collagen; matrix metalloproteinases; target organ damage; MATRIX METALLOPROTEINASES; TISSUE INHIBITOR; HEART-FAILURE; DIASTOLIC DYSFUNCTION; CARDIOVASCULAR RISK; MATRIX-METALLOPROTEINASE-9; FIBROSIS; TIMP-1;
D O I
10.1097/HJH.0b013e3283614c1c
中图分类号
R6 [外科学];
学科分类号
100210 [外科学];
摘要
Objective:Increasing experimental evidence indicates that alterations in the extracellular matrix are implicated in hypertension and its chronic complications. Selected markers of extracellular matrix metabolism were investigated as potential biomarkers for hypertensive remodelling and correlated with the severity and extent of target organ damage (TOD) in patients with essential hypertension.Methods:We studied 159 consecutive patients being treated for essential hypertension. An exhaustive evaluation of the heart, kidney and blood vessel damage was performed, and plasma levels of plasma procollagen type I (PICP), matrix metalloproteinase-1 (MMP-1) and its inhibitor (tissue inhibitor metalloproteinase-1, TIMP-1) were determined. Patients were categorized into four groups: no TOD (33 patients), level 1 TOD (52 patients), level 2 TOD (44 patients) and level 3 TOD (30 patients).Results:The serum levels of MMP-1 and TIMP-1 were higher in patients with TOD than in hypertensive patients without TOD. Increasing levels of these molecules were progressively associated with an increase in the number of organs damaged, with highest levels of markers in patients with level 3 TOD (heart, kidney and blood vessels). There were no differences in PICP levels between groups. We found a slight but significant correlation between TIMP-1 and all hypertensive organ damage. Logistic regression analysis showed that age, smoking, diabetes mellitus, abdominal perimeter, MMP-1 and TIMP-1 were independently related to the level of TOD.Conclusion:Circulating concentration of MMP-1 and TIMP-1 is associated with an extended hypertensive disease, with more TOD. TIMP-1 may have a role as a biomarker of total remodelling burden in hypertensive patients.
引用
收藏
页码:1611 / 1617
页数:7
相关论文
共 26 条
[1]
Matrix metalloproteinases/tissue inhibitors of metalloproteinases - Relationship between changes in proteolytic determinants of matrix composition and structural, functional, and clinical manifestations of hypertensive heart disease [J].
Ahmed, SH ;
Clark, LL ;
Pennington, WR ;
Webb, CS ;
Bonnema, DD ;
Leonardi, AH ;
McClure, CD ;
Spinale, FG ;
Zile, MR .
CIRCULATION, 2006, 113 (17) :2089-2096
[2]
Contribution of circulating biomarkers to unravel the role of extracellular matrix in hypertensive cardiac remodelling [J].
Beaumont, Javier ;
Gonzalez, Arantxa ;
Lopez, Begona ;
Ravassa, Susana ;
Diez, Javier .
JOURNAL OF HYPERTENSION, 2012, 30 (01) :34-37
[3]
Metalloproteinase inhibition ameliorates hypertension and prevents vascular dysfunction and remodeling in renovascular hypertensive rats [J].
Castro, Michele A. ;
Rizzi, Elen ;
Figueiredo-Lopes, Livia ;
Fernandes, Karla ;
Bendhack, Lusiane A. ;
Pitol, Dimitrius Leonardo ;
Gerlach, Raquel E. ;
Tanus-Santos, Jose E. .
ATHEROSCLEROSIS, 2008, 198 (02) :320-331
[4]
Matrix metalloproteinases: Targets for doxycycline to prevent the vascular alterations of hypertension [J].
Castro, Michele M. ;
Tanus-Santos, Jose E. ;
Gerlach, Raquel F. .
PHARMACOLOGICAL RESEARCH, 2011, 64 (06) :567-572
[5]
Matrix metalloproteinase-2,-9, and tissue inhibitor of metalloproteinase-1 in patients with hypertension [J].
Derosa, Giuseppe ;
D'Angelo, Angela ;
Ciccarelli, Leonardina ;
Piccinni, Mario N. ;
Pricolo, Fabio ;
Salvadeo, Sibilla ;
Montagna, Lorenza ;
Gravina, Alessia ;
Ferrari, Ilaria ;
Galli, Simona ;
Paniga, Sonia ;
Tinelli, Carmine ;
Cicero, Arrigo F. G. .
ENDOTHELIUM-JOURNAL OF ENDOTHELIAL CELL RESEARCH, 2006, 13 (03) :227-231
[6]
Downregulation of vascular matrix metalloproteinase inducer and activator proteins in hypertensive patients [J].
Ergul, A ;
Portik-Dobos, V ;
Hutchinson, J ;
Franco, J ;
Anstadt, MP .
AMERICAN JOURNAL OF HYPERTENSION, 2004, 17 (09) :775-782
[7]
Circulating matrix metalloproteinases and their inhibitors in hypertension [J].
Fontana, Vanessa ;
Silva, Pamela S. ;
Gerlach, Raquel F. ;
Tanus-Santos, Jose E. .
CLINICA CHIMICA ACTA, 2012, 413 (7-8) :656-662
[8]
Matrix Metalloproteinases: Discrete Elevations in Essential Hypertension and Hypertensive End-Stage Renal Disease [J].
Friese, Ryan S. ;
Rao, Fangwen ;
Khandrika, Srikrishna ;
Thomas, Brenda ;
Ziegler, Michael G. ;
Schmid-Schoenbein, Geert W. ;
O'Connor, Daniel T. .
CLINICAL AND EXPERIMENTAL HYPERTENSION, 2009, 31 (07) :521-533
[9]
Filling Pressures and Collagen Metabolism in Hypertensive Patients With Heart Failure and Normal Ejection Fraction [J].
Gonzalez, Arantxa ;
Lopez, Begona ;
Querejeta, Ramon ;
Zubillaga, Elena ;
Echeverria, Tomas ;
Diez, Javier .
HYPERTENSION, 2010, 55 (06) :1418-1424
[10]
Relations of serum MMP-9 and TIMP-1 levels to left ventricular measures and cardiovascular risk factors: a population-based study [J].
Hansson, Jonas ;
Lind, Lars ;
Hulthe, Johannes ;
Sundstrom, Johan .
EUROPEAN JOURNAL OF CARDIOVASCULAR PREVENTION & REHABILITATION, 2009, 16 (03) :297-303